Cargando…

ALP bouncing and LDH normalization in bone metastatic castration-resistant prostate cancer patients under therapy with Enzalutamide: an exploratory analysis

BACKGROUND: In bone metastatic castration-resistant prostate cancer (bmCRPC) treated with Enzalutamide commonly used prostate-specific antigen (PSA) can be misleading since initial PSA-flares may occur. In other therapies, bouncing of alkaline phosphatase (ALP-bouncing) was shown to be a promising s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schlack, Katrin, Krabbe, Laura-Maria, Rahbar, Kambiz, Isenberg, Karoline, Semjonow, Axel, Schrader, Andres Jan, Boegemann, Martin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2021
Materias:	Original Article on Management of Advanced Genitourinary Malignancies
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8575579/ https://www.ncbi.nlm.nih.gov/pubmed/34804841 http://dx.doi.org/10.21037/tau-20-1117

Ejemplares similares

The prognostic potential of alkaline phosphatase and lactic acid dehydrogenase in bmCRPC patients without significant PSA response under enzalutamide
por: Poteska, Renata, et al.
Publicado: (2022)

Assessment of prognosis by established prognosis scores and physicians’ judgement in mRCC patients: an analysis of the STAR-TOR registry
por: Boegemann, Martin, et al.
Publicado: (2021)

The Role of the Neutrophil to Lymphocyte Ratio for Survival Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone
por: Boegemann, Martin, et al.
Publicado: (2017)

Early Prediction of Therapy Response to Abiraterone Acetate Using PSA Subforms in Patients with Castration Resistant Prostate Cancer
por: Schlack, Katrin, et al.
Publicado: (2016)

Influence of Statins on Survival Outcome in Patients with Metastatic Castration Resistant Prostate Cancer Treated with Abiraterone Acetate
por: Boegemann, Martin, et al.
Publicado: (2016)

A marrow-minded look at immune checkpoint blockade resistance in metastatic castration resistant prostate cancer
por: Fonseca, Nicolette M., et al.
Publicado: (2021)

Finding the optimal treatment sequence in metastatic castration-resistant prostate cancer—a narrative review
por: Maurice Dror, Corinne, et al.
Publicado: (2021)

Narrative review: prostate-specific membrane antigen-radioligand therapy in metastatic castration-resistant prostate cancer
por: Lunger, Lukas, et al.
Publicado: (2021)

KDM5D predicts response to docetaxel chemotherapy in metastatic castration resistant prostate cancer patients
por: Schäfer, Georg, et al.
Publicado: (2021)

Comparison of circulating tumor cells and AR-V7 as clinical biomarker in metastatic castration-resistant prostate cancer patients
por: Schlack, Katrin, et al.
Publicado: (2022)

Variant histology in bladder cancer: how it should change the management in non-muscle invasive and muscle invasive disease?
por: Klaile, Yvonne, et al.
Publicado: (2016)

Dynamic changes of alkaline phosphatase are strongly associated with PSA-decline and predict best clinical benefit earlier than PSA-changes under therapy with abiraterone acetate in bone metastatic castration resistant prostate cancer
por: Mikah, Phillip, et al.
Publicado: (2016)

Preface to “Management of advanced genitourinary malignancies”
por: Todenhöfer, Tilman
Publicado: (2021)

Second line chemotherapy and visceral metastases are associated with poor survival in patients with mCRPC receiving (177)Lu-PSMA-617
por: Kessel, Katharina, et al.
Publicado: (2019)

Lutetium-177 Labelled PSMA Targeted Therapy in Advanced Prostate Cancer: Current Status and Future Perspectives
por: Seitzer, Konstantin Egon, et al.
Publicado: (2021)

Visceral Metastasis Predicts Response to New Hormonal Agents in Metastatic Castration-Sensitive Prostate Cancer
por: Yekedüz, Emre, et al.
Publicado: (2023)

A prognostic score for overall survival in patients treated with abiraterone in the pre- and post-chemotherapy setting
por: Boegemann, Martin, et al.
Publicado: (2019)

Optimization of Radium-223 Treatment of Castration-resistant Prostate Cancer Based on the Burden of Skeletal Metastasis and Clinical Parameters
por: Shariftabrizi, Ahmad, et al.
Publicado: (2023)

(177)Lu-PSMA Therapy for Metastatic Castration-Resistant Prostate Cancer: A Mini-Review of State-of-the-Art
por: AlSadi, Rahaf, et al.
Publicado: (2022)

Real-World Treatment Patterns Among Patients With Metastatic Castration-Resistant Prostate Cancer: Results From an International Study
por: Barata, Pedro C, et al.
Publicado: (2023)

Real-World Treatment Trends Among Patients with Metastatic Castration-Sensitive Prostate Cancer: Results from an International Study
por: Barata, Pedro C, et al.
Publicado: (2023)

Oncological validation of bone turnover markers c-terminal telopeptide of type I collagen (1CTP) and peptides n-terminal propeptide of type I procollagen (P1NP) in patients with prostate cancer and bone metastases
por: Aufderklamm, Stefan, et al.
Publicado: (2021)

Characteristics of upper urinary tract urothelial carcinoma in the context of bladder cancer: a narrative review
por: Giudici, Nicola, et al.
Publicado: (2021)

Systemic treatment of penile squamous cell carcinoma—hurdles and hopes of preclinical models and clinical regimens: a narrative review
por: Thomas, Anita, et al.
Publicado: (2021)

Current treatment options for newly diagnosed metastatic hormone-sensitive prostate cancer—a narrative review
por: Ong, Sean, et al.
Publicado: (2021)

Treatment options for advanced urothelial cancer after progression on chemotherapy and immune checkpoint inhibitors: a literature review
por: Koshkin, Vadim S., et al.
Publicado: (2021)

Prostate specific membrane antigen-radio guided surgery using Cerenkov luminescence imaging—utilization of a short-pass filter to reduce technical pitfalls
por: Darr, Christopher, et al.
Publicado: (2021)

Narrative review of challenges in the management of advanced neuroendocrine prostate cancer
por: Okasho, Kosuke, et al.
Publicado: (2021)

Narrative review of developing new biomarkers for decision making in advanced testis cancer
por: Nappi, Lucia, et al.
Publicado: (2021)

Combination therapies involving checkpoint-inhibitors for treatment of urothelial carcinoma: a narrative review
por: Schulz, Gerald B., et al.
Publicado: (2021)

Update on systemic treatment of upper tract urothelial carcinoma: a narrative review of the literature
por: Gust, Kilian M., et al.
Publicado: (2021)

ADXS31142 Immunotherapy ± Pembrolizumab Treatment for Metastatic Castration-Resistant Prostate Cancer: Open-Label Phase I/II KEYNOTE-046 Study
por: Stein, Mark N, et al.
Publicado: (2022)

Plasma Exosomal AKR1C3 mRNA Expression Is a Predictive and Prognostic Biomarker in Patients with Metastatic Castration-Resistant Prostate Cancer
por: Zhu, Sha, et al.
Publicado: (2022)

Talazoparib, a Poly(ADP-ribose) Polymerase Inhibitor, for Metastatic Castration-resistant Prostate Cancer and DNA Damage Response Alterations: TALAPRO-1 Safety Analyses
por: Mehra, Niven, et al.
Publicado: (2022)

Pictorial essay: Congenital anomalies of male urethra in children
por: Jana, Manisha, et al.
Publicado: (2011)

Case series: Diffusion weighted MRI appearance in prostatic abscess
por: Singh, Paramjeet, et al.
Publicado: (2011)

The Back Alley Revisited: Sepsis after Attempted Self-Induced Abortion
por: Saultes, Teresa A, et al.
Publicado: (2009)

Non-Traumatic Urologic Emergencies in Men: A Clinical Review
por: Kessler, Chad S, et al.
Publicado: (2009)

Diffusion-Weighted Magnetic Resonance Imaging for the Evaluation of Prostate Cancer: Optimal B Value at 3T
por: Koo, Ji Hyun, et al.
Publicado: (2013)

Catamenial pneumothorax caused by thoracic endometriosis
por: Maniglio, Paolo, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_ssaghhkbkr7kimrm2uqkemg22e